Intrinsic and acquired resistance mechanisms of alectinib in ALK rearranged cells

被引：0
|
作者：
Hibino, Yukiko [1 ]
Takaaki, Sasaki [1 ]
Minami, Yoshinori [1 ]
Janne, Pasi A. [2 ]
Ohsaki, Yoshinobu [1 ]
机构：
[1] Asahikawa Med Univ, Asahikawa, Hokkaido, Japan
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Acquired ALK L1152R Mutation Confers Resistance to Ceritinib and Predicts Response to Alectinib
    Tchekmedyian, Nishan
    Ali, Siraj M.
    Miller, Vincent A.
    Haura, Eric B.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (07) : E87 - E88
  • [42] Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients
    Niu, Xiaomin
    Perdomo, Sandra
    Blackhall, Fiona
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 : S239 - S245
  • [43] Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
    Recondo, Gonzalo
    Mezquita, Laura
    Facchinetti, Francesco
    Planchard, David
    Gazzah, Anas
    Bigot, Ludovic
    Rizvi, Ahsan Z.
    Frias, Rosa L.
    Thiery, Jean Paul
    Scoazec, Jean-Yves
    Sourisseau, Tony
    Howarth, Karen
    Deas, Olivier
    Samofalova, Dariia
    Galissant, Justine
    Tesson, Pauline
    Braye, Floriane
    Naltet, Charles
    Lavaud, Pernelle
    Mahjoubi, Linda
    Abou Lovergne, Aurelie
    Vassal, Gilles
    Bahleda, Rastilav
    Hollebecque, Antoine
    Nicotra, Claudio
    Ngo-Camus, Maud
    Michiels, Stefan
    Lacroix, Ludovic
    Richon, Catherine
    Auger, Nathalie
    De Baere, Thierry
    Tselikas, Lambros
    Solary, Eric
    Angevin, Eric
    Eggermont, Alexander M.
    Andre, Fabrice
    Massard, Christophe
    Olaussen, Ken A.
    Soria, Jean-Charles
    Besse, Benjamin
    Friboulet, Luc
    CLINICAL CANCER RESEARCH, 2020, 26 (01) : 242 - 255
  • [44] Activation of EGFR bypass signaling through TGFα overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells
    Tani, Tetsuo
    Yasuda, Hiroyuki
    Hamamoto, Junko
    Kuroda, Aoi
    Arai, Daisuke
    Ishioka, Kota
    Ohgino, Keiko
    Kawada, Ichiro
    Naoki, Katsuhiko
    Yuichiro, Hayashi
    Betsuyaku, Tomoko
    Soejima, Kenzo
    CANCER RESEARCH, 2015, 75
  • [45] Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer
    Kim, Soyeon
    Kim, Tae Min
    Kim, Dong-Wan
    Go, Heounjeong
    Keam, Bhumsuk
    Lee, Se-Hoon
    Ku, Ja-Lok
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 (04) : 415 - 422
  • [46] Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?
    Thai, A. A.
    Solomon, B. J.
    ANNALS OF ONCOLOGY, 2018, 29 (11) : 2160 - 2162
  • [47] Alectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study
    Dagogo-Jack, Ibiayi
    Cooper, Alissa J.
    Johnson, Bruce E.
    Gainor, Justin F.
    Lin, Jessica J.
    Sequist, Lecia V.
    Piotrowska, Zofia
    Digumarthy, Subba R.
    Mino-Kenudson, Mari
    Muzikansky, Alona
    Shaw, Alice T.
    LUNG CANCER, 2025, 199
  • [48] Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
    Shiihara, Jun
    Ohyanagi, Fumiyoshi
    Amari, Hikari
    Toda, Minemichi
    Tahara, Hiroki
    Yuzawa, Motoi
    Maeda, Yuki
    Nomura, Motoko
    Mizushina, Yoshiko
    Nagai, Yoshiaki
    Ohta, Hiromitsu
    Yamaguchi, Yasuhiro
    THORACIC CANCER, 2021, 12 (17) : 2420 - 2423
  • [49] Diverse biological mechanisms drive resistance to Lorlatinib in ALK-rearranged Lung Cancer
    Recondo, Gonzalo
    Mezquita, Laura
    Planchard, David
    Gazzah, Anas
    Facchinetti, Francesco
    Bigot, Ludovic
    Rizvi, Ahsan Z.
    Thiery, Jean-Paul
    Scoazec, Jean-Yves
    Frias, Rosa L.
    Sourisseau, Tony
    Mahjoubi, Linda
    Galissant, Justine
    Abou-Lovergne, Aurelie
    Vassal, Gilles
    Bahleda, Rastislav
    Hollebecque, Antoine
    Nicotra, Claudio
    Ngocamus, Maud
    Michiels, Stefan
    Lacroix, Ludovic
    Richon, Catherine
    Auger, Nathalie
    De Baere, Thierry
    Deschamps, Frederic
    Salary, Eric
    Olaussen, Ken A.
    Angevin, Eric
    Eggermont, Alexander
    Andre, Fabrice
    Massard, Christophe
    Soria, Jean-Charles
    Besse, Benjamin
    Friboulet, Luc
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC
    Zheng, Jing
    Sun, Wenjia
    Chen, Wenhong
    Zhou, Jianying
    Zhou, Jianya
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E150 - E153
12345